Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07316062

A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China

This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Non-Small-Cell Lung Bronchial Neoplasms Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site

Beijing, China

Location status: Recruiting

Location contact

Shugeng Gao

CONTACT

[email protected]

About this study

The primary objective of this study is to understand the evolution of initial treatment patterns among patients with early-stage (I-III) NSCLC.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Stage I-III at initial NSCLC diagnosis
  • Aged ≥18 years at first diagnosis of NSCLC
  • Timeframe of NSCLC diagnosis:

For DE1: diagnosed with NSCLC during the period between May 1st 2025 and December 31st 2025 For DE2: diagnosed with NSCLC during the period between May 1st 2026 and December 31st 2026 For DE3: diagnosed with NSCLC during the period between May 1st 2027 and December 31st 2027

Exclusion criteria

  • NSCLC is not the primary cancer diagnosis
  • Patients with a recent history of other tumor or concurrent other tumor
  • Patients participating in interventional clinical trials at time of initial diagnosis
  • Patients with positive pregnancy status at the time of diagnosis

Treatment and study plan

Primary outcomes

  1. Treatment Patterns

    Time frame: Up to 50 months

    Proportion of patients with different treatment regimens

  2. Proportion of unresected patients in SI/II/III

    Time frame: Up to 50 months

    Proportion of patients who are unresected among SI/II/III NSCLC patients enrolled, respectively

  3. CRT rate in USIII

    Time frame: Up to 50 months

    Proportion of patients who have CRT regimen among unresected SIII patients enrolled

Secondary outcomes

  1. Treatment Duration

    Time frame: Up to 50 months

    TKI treatment duration and discontinuation reason in EGFRm patients

    • Duration of treatment
    • Treatment discontinuation (time to discontinuation, and reason for discontinuation)

  2. Patterns of recurrence

    Time frame: Up to 50 months

    Type of recurrence following initial treatment regimen (Loco-regional recurrence, distant recurrence, other)

  3. Guideline adoption rate

    Time frame: Up to 50 months

    Resected EGFRm Stage IB-III

    • Proportion of patients received guideline recommended TKI adjuvant regimen among a. resected EGFRm Stage IB-III patients; b. patients with TKI adjuvant therapy Unresected Stage III
    • Proportion of patients received guideline recommended systemic IO and TKI regimens among patients who received CRT

Study contacts

Contact information is provided by the study sponsor or research team.

AstraZeneca Clinical Study Information Center

CONTACT

[email protected]

1-877-240-9479

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

A Multi-centre Chart Review Study on the Treatment Patterns and Outcomes of Stage I-III Non-Small Cell Lung Cancer in China

Acronym: MAP

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Jan 5, 2026
Registry last updated
Jul 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.